Implanted-Pump Bortezomib Delivery for Brain Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for malignant gliomas, such as glioblastoma, are ineffective due to tumor recurrence and resistance to chemotherapy, limited by the blood-brain barrier and systemic side effects, and proteasome inhibitors like bortezomib face delivery issues and toxicity concerns.
Innovation Solution
Administering bortezomib directly into brain tumors using an implanted pump to bypass the blood-brain barrier and minimize systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If systemic chemotherapy is administered to treat brain tumors, then the drug can reach the tumor through the bloodstream, but the blood-brain barrier prevents effective delivery and the drug distributes throughout the entire body causing systemic side effects
Solution Approach 1:
The patent applies local quality by transforming systemic chemotherapy into localized intratumoral delivery. The chemotherapeutic agent is administered directly into the tumor tissue rather than systemically, creating a high concentration at the target site while minimizing exposure to healthy tissues. This resolves the contradiction by achieving effective drug delivery to the tumor (improving_feature) while avoiding systemic distribution and its associated side effects (worsening_feature).
Solution Approach 2:
The patent uses an implantable pump device as an intermediary to deliver the chemotherapeutic agent directly into the tumor. This intermediary system enables precise local administration, bypassing the blood-brain barrier issues and systemic distribution problems. The pump acts as a mediator between the drug reservoir and the tumor tissue, ensuring controlled local delivery that achieves therapeutic concentrations at the tumor site without causing systemic side effects.
2Reliability
If proteasome inhibitors like bortezomib are administered systemically, then the drug can treat various tumors, but delivery across the blood-brain barrier is limited and the drug causes systemic toxicity
Solution Approach 1:
The patent applies local quality by administering bortezomib directly into the brain tumor tissue rather than systemically. This creates a high local concentration of the proteasome inhibitor at the tumor site, ensuring reliable tumor treatment efficacy (improving_feature) while minimizing systemic exposure and toxicity (worsening_feature). The localized delivery overcomes the blood-brain barrier limitation by bypassing it entirely through direct intratumoral injection.
Solution Approach 2:
The patent uses an implantable pump as an intermediary device to deliver bortezomib directly into the tumor. This intermediary system enables precise control of drug delivery, ensuring adequate therapeutic levels are achieved within the tumor (improving_feature) while preventing systemic distribution that would cause toxicity (worsening_feature).
3Adaptability or versatility
If chemotherapy is distributed systemically throughout the entire body, then the treatment can reach all potential tumor sites, but undesirable side effects occur in non-tumor areas
Solution Approach 1:
The patent applies local quality by concentrating the chemotherapeutic agent exclusively at the tumor site through intratumoral delivery. This eliminates exposure of healthy tissues to the drug, thereby preventing side effects in non-tumor areas (worsening_feature) while maintaining effective treatment coverage at the target site (improving_feature). The localized approach replaces systemic distribution with site-specific therapy.
Data Source
AI summary
A method of administering bortezomib into a brain tumor by a pump implanted in a brain of a subject. The method includes administering a drug to a tumor in a central nervous system of a subject, the method comprising, delivering a therapeutically effective amount of the drug into a brain, tumor by a pump implanted in a brain of the subject, wherein administration of the drag to the subject in the central nervous system is contraindicated because of toxicity of the drug.